Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaclyn Beca

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Pharmacoeconomics|January 17, 2013
The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in CanadaJean H E Yong, Jaclyn Beca, Jeffrey S Hoch
Pharmacoeconomics - Open|February 15, 2018
Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)Lisa Masucci, Jaclyn Beca, Mona Sabharwal, et al.
Pharmacoeconomics|October 2, 2019
A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness AnalysisSandjar Djalalov, Jaclyn Beca, Emmanuel M Ewara, et al.
Pharmacoeconomics|November 8, 2017
Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology AssessmentJaclyn Beca, Don Husereau, Kelvin K W Chan, et al.
Pharmacoeconomics|May 6, 2015
Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?Jeffrey S Hoch, Jaclyn Beca, Mona Sabharwal, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 1, 2019
Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancerJaclyn Beca, Habeeb Majeed, Kelvin K W Chan, et al.
Cancer Medicine|August 15, 2020
The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphomaSteven Habbous, Helen Guo, Jaclyn Beca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2014
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancerSandjar Djalalov, Jaclyn Beca, Jeffrey S Hoch, et al.
Molecular Diagnosis & Therapy|November 29, 2012
Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicineSandjar Djalalov, Jean Yong, Jaclyn Beca, et al.
Cancer|January 9, 2020
Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeuticsCameron M Phillips, Ambica Parmar, Helen Guo, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Pharmacoeconomics|January 17, 2013
The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in CanadaJean H E Yong, Jaclyn Beca, Jeffrey S Hoch
Pharmacoeconomics - Open|February 15, 2018
Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)Lisa Masucci, Jaclyn Beca, Mona Sabharwal, et al.
Pharmacoeconomics|October 2, 2019
A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness AnalysisSandjar Djalalov, Jaclyn Beca, Emmanuel M Ewara, et al.
Pharmacoeconomics|November 8, 2017
Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology AssessmentJaclyn Beca, Don Husereau, Kelvin K W Chan, et al.
Pharmacoeconomics|May 6, 2015
Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?Jeffrey S Hoch, Jaclyn Beca, Mona Sabharwal, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 1, 2019
Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancerJaclyn Beca, Habeeb Majeed, Kelvin K W Chan, et al.
Cancer Medicine|August 15, 2020
The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphomaSteven Habbous, Helen Guo, Jaclyn Beca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2014
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancerSandjar Djalalov, Jaclyn Beca, Jeffrey S Hoch, et al.
Molecular Diagnosis & Therapy|November 29, 2012
Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicineSandjar Djalalov, Jean Yong, Jaclyn Beca, et al.
Cancer|January 9, 2020
Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeuticsCameron M Phillips, Ambica Parmar, Helen Guo, et al.
Pageof 3